-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2024.
- Avalo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$35.3M, a 333% decline year-over-year.
- Avalo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$35.1M, a 11.4% decline year-over-year.
- Avalo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$35.1M, a 11.4% decline from 2023.
- Avalo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.5M, a 24.3% increase from 2022.
- Avalo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$41.7M, a 50.6% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)